Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO6870868 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| RO6870868 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RO6870868 | DRUG | Single ascending doses |
| placebo | DRUG | Single ascending doses |
Inclusion Criteria: * Healthy male and female subjects, 18 to 65 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history and a complete physical examination * Women of non-childbearing potential inc...
RO6870868 is an investigational small molecule developed by Roche Holding AG. It has been studied in a Phase 1 clinical trial in healthy volunteers. The specific disease or condition it is intended to treat has not been disclosed, so its therapeutic use is not publicly defined.
RO6870868 is developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the clinical program for this compound.
RO6870868 is in Phase 1 development. It is an investigational drug and is not approved for any indication. The program has completed one Phase 1 trial, and no active trials are currently listed for this compound.
RO6870868 has been evaluated in one completed Phase 1 trial, NCT01911611, titled A Study of RO6870868 in Healthy Volunteers. The trial enrolled 60 participants in the Netherlands, was randomized, double blind, and placebo controlled, and included adults 18 years and older.
Yes. The Phase 1 trial NCT01911611 for RO6870868 was conducted in healthy volunteers rather than in patients with a specific disease. It enrolled 60 participants, used a randomized, double blind, placebo controlled design, and was run in the Netherlands. The study has been completed.